These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20081377)

  • 1. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
    Urva SR; Balthasar JP
    MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
    Urva SR; Yang VC; Balthasar JP
    J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
    Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
    J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
    Abuqayyas L; Balthasar JP
    AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
    Polli JR; Engler FA; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
    Abuqayyas L; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.
    Thomas VA; Balthasar JP
    AAPS J; 2016 Jul; 18(4):923-32. PubMed ID: 27029796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
    Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
    Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasma.
    Urva SR; Yang VC; Balthasar JP
    J Immunoassay Immunochem; 2010; 31(1):1-9. PubMed ID: 20391013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
    Boxer GM; Abassi AM; Pedley RB; Begent RH
    Br J Cancer; 1994 Feb; 69(2):307-14. PubMed ID: 7507692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applicability of carcinoembryonic antigen-specific monoclonal antibodies to radioimmunoguided surgery for human colorectal carcinoma.
    Kim JC; Kim WS; Ryu JS; Oh SJ; Lee DH; Koo KH; Roh SA; Kim HC; Yu CS; Kang GH; Bodmer WF
    Cancer Res; 2000 Sep; 60(17):4825-9. PubMed ID: 10987293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice.
    Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD
    Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
    Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA
    Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor targeting with radiolabeled antibodies in a human carcinoembryonic antigen transgenic mouse model.
    Szalai G; Williams LE; Primus FJ
    Int J Cancer; 2000 Mar; 85(6):751-6. PubMed ID: 10709090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
    Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
    J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
    Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
    Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma.
    Rajkumar VS; Boxer G; Robson M; Muddle J; Papastavrou Y; Pedley RB
    Tumour Biol; 2012 Dec; 33(6):2019-29. PubMed ID: 22833213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.